Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials

Mirna Abd El Aziz,Oscar Cahyadi,Juris J. Meier,Wolfgang E. Schmidt,Michael A. Nauck

DOI: https://doi.org/10.1111/dom.13924

2019-12-11

Diabetes, Obesity and Metabolism

Abstract:Background/aimsSome epidemiological data have suggested an elevated risk for acute pancreatitis and pancreatic cancer after exposure to GLP‐1 receptor agonists and DPP‐4 inhibitors. Recently, such outcomes have been assessed and adjudicated as adverse events of special interest in cardiovascular outcomes studies. MethodsWe performed a meta‐analysis of cases of acute pancreatitis and pancreatic cancer as well as any malignant neoplasm reported in cardiovascular outcomes trials (CVOTs) with GLP‐1 receptor agonists and DPP‐4 inhibitors. The numbers of cases observed with active drug or placebo (both on a background of standard care) were related to patient years of observation. Rate ratios and their confidence intervals were calculated for the individual agents as well as for the classes of GLP‐1 receptor agonists and DPP‐4 inhibitors. ResultsNeither data on individual CVOTs of GLP‐1 receptor agonists nor their meta‐analysis (rate ratio: 1.05 [0.78‐1.41]) indicated a significantly elevated risk for acute pancreatitis. All individual DPP‐4 inhibitors displayed a non‐significant trend towards an increased risk for acute pancreatitis, which was significant in the meta‐analysis (1.75 [1.14‐2.70]; p = 0.01).Neither GLP‐1 receptor agonists, nor DPP‐4 inhibitors were associated with a significantly elevated or reduced risk for pancreatic cancer or for the totality of all malignant neoplasms. ConclusionsBased on a large database of randomized, placebo‐controlled, prospective cardiovascular outcomes studies with GLP‐1 receptor agonists and DPP‐4 inhibitors, no signal for pancreatic cancer or any malignant neoplasms was detected. However, a 75% risk increase for development of an acute pancreatitis was seen in the meta‐analysis of DPP‐4 inhibitor CVOTs.This article is protected by copyright. All rights reserved.